CD44: A key player in breast cancer.

CD44 is a principal transmembrane hyluronate receptor, which acts as a hook between Extracellular Matrix and the cytoskeleton. CD44 is up regulated in breast cancer, which in turn helps in tumor progression and metastasis. There has been a lot of attention given to CD44 in recent years because of the discovery, CD44+/CD24- lineage marks breast cancer stem cells. Recent clinical and experimental findings show that CD44 is involved in the tumor associated proliferation, invasion, migration, and in many pathways involved in maintaining cancer cells which inturn are correlated with patient's survival. All these findings make CD44 as a potential target for breast cancer treatment. The methods of literature search for this article include Pubmed, BMC cancer and other printed journal article.

[1]  Hwai-Shi Wang,et al.  CD44 crosslinking-mediated matrix metalloproteinase-9 relocation in breast tumor cells leads to enhanced metastasis. , 2007, International journal of oncology.

[2]  A. Shiau,et al.  Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. , 2008, Cancer research.

[3]  Jeong-Seok Nam,et al.  OCT4 Expression Enhances Features of Cancer Stem Cells in a Mouse Model of Breast Cancer , 2011, Laboratory animal research.

[4]  L. Howell,et al.  Diagnostic Utility of CD44 Standard, CD44v6, and CD44v3-10 Expression in Adenocarcinomas Presenting in Serous Fluids , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  L. Bourguignon,et al.  Hyaluronan-CD44 Interaction Activates Stem Cell Marker Nanog, Stat-3-mediated MDR1 Gene Expression, and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor Cells* , 2008, Journal of Biological Chemistry.

[6]  H. Bailey,et al.  Expression of CD44s, CD44v6, and Hyaluronan Across the Spectrum of Normal-hyperplasia-carcinoma in Breast , 2008, Applied immunohistochemistry & molecular morphology : AIMM.

[7]  L. Sherman,et al.  CD44 Associates With EGFR and erbB2 in Metastasizing Mammary Carcinoma Cells , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[8]  Kornelia Polyak,et al.  Identification of CD44v6+/CD24− breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies , 2009, Laboratory Investigation.

[9]  Ekaterina I. Galanzha,et al.  Nanotechnology‐based molecular photoacoustic and photothermal flow cytometry platform for in‐vivo detection and killing of circulating cancer stem cells , 2009, Journal of biophotonics.

[10]  Chen Wang,et al.  CD44v4 Is a Major E-Selectin Ligand that Mediates Breast Cancer Cell Transendothelial Migration , 2008, PloS one.

[11]  S. Saydam,et al.  Predicting invasive phenotype with CDH1, CDH13, CD44, and TIMP3 gene expression in primary breast cancer , 2009, Cancer science.

[12]  A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone. , 2009, Chinese medical journal.

[13]  Ole N Jensen,et al.  Metastasis-related Plasma Membrane Proteins of Human Breast Cancer Cells Identified by Comparative Quantitative Mass Spectrometry* , 2009, Molecular & Cellular Proteomics.

[14]  Voranuch Thanakit,et al.  The association of co-expression of CD44v4/MMP-9 with different nodal status in high-grade breast carcinoma patients. , 2005, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[15]  S. Ghatak,et al.  Regulation of MDR1 Expression and Drug Resistance by a Positive Feedback Loop Involving Hyaluronan, Phosphoinositide 3-Kinase, and ErbB2*♦ , 2005, Journal of Biological Chemistry.

[16]  M. Mahalingam,et al.  Prognostic value of E-cadherin, beta-catenin, CD44v6, and HER2/neu in metastatic cutaneous adenocarcinoma. , 2009, Archives of pathology & laboratory medicine.

[17]  J. Grifo,et al.  Oct-4 expression in inner cell mass and trophectoderm of human blastocysts. , 2000, Molecular human reproduction.

[18]  Wen-Zhi Chen,et al.  Changes in biologic characteristics of breast cancer treated with high-intensity focused ultrasound. , 2003, Ultrasound in medicine & biology.

[19]  S. Ghatak,et al.  REGULATION OF MDR 1 EXPRESSION AND DRUG RESISTANCE BY A POSITIVE FEEDBACK LOOP INVOLVING HYALURONAN , PHOSPHOINOSITIDE 3-KINASE AND ERBB 2 * , 2005 .

[20]  G. Wong,et al.  Hyaluronan-mediated CD44 Interaction with p300 and SIRT1 Regulates β-Catenin Signaling and NFκB-specific Transcription Activity Leading to MDR1 and Bcl-xL Gene Expression and Chemoresistance in Breast Tumor Cells* , 2009, Journal of Biological Chemistry.

[21]  M. Asadi-lari,et al.  CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. , 2009, Cancer immunity.

[22]  Zhihao Lu,et al.  [Detection of breast cancer stem cells and the expression of key molecules in Hedgehog signaling pathway]. , 2008, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences.

[23]  M. Abdraboh,et al.  In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. , 2007, The American journal of pathology.

[24]  R. Epstein,et al.  Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells , 2002, British Journal of Cancer.

[25]  Jun Tang,et al.  [Expression and clinical significance of adhesive molecule CD44v6 in breast invasive ductal carcinoma]. , 2006, Ai zheng = Aizheng = Chinese journal of cancer.

[26]  Chen-Yang Shen,et al.  Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[27]  C. Yip,et al.  CD 44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast , 2007 .

[28]  H. Satoh,et al.  Histiocytoid breast carcinoma: Solid variant of invasive lobular carcinoma with decreased expression of both E‐cadherin and CD44 epithelial variant , 2005, Pathology international.

[29]  P. Johnston,et al.  CD44 Potentiates the Adherence of Metastatic Prostate and Breast Cancer Cells to Bone Marrow Endothelial Cells , 2004, Cancer Research.

[30]  O. Watanabe,et al.  Expression of a CD44 variant and VEGF-C and the implications for lymphatic metastasis and long-term prognosis of human breast cancer. , 2005, Journal of experimental & clinical cancer research : CR.

[31]  S. Richard,et al.  Identification of a Sam68 Ribonucleoprotein Complex Regulated by Epidermal Growth Factor* , 2009, The Journal of Biological Chemistry.

[32]  Maria Athelogou,et al.  Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  I. Ellis,et al.  A CD44−/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer , 2012, Breast Cancer Research and Treatment.

[34]  S. Stamm,et al.  Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients , 2008, Journal of Cancer Research and Clinical Oncology.

[35]  G. Wong,et al.  Hyaluronan-CD44 Interaction with Protein Kinase Cϵ Promotes Oncogenic Signaling by the Stem Cell Marker Nanog and the Production of MicroRNA-21, Leading to Down-regulation of the Tumor Suppressor Protein PDCD4, Anti-apoptosis, and Chemotherapy Resistance in Breast Tumor Cells* , 2009, The Journal of Biological Chemistry.

[36]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[37]  T. Misteli,et al.  Signalling , cell cycle and pluripotency in embryonic stem cells , 2002 .

[38]  Hwai-Shi Wang,et al.  CD44 Cross-linking induces integrin-mediated adhesion and transendothelial migration in breast cancer cell line by up-regulation of LFA-1 (αLβ2) and VLA-4 (α4β1) , 2005 .

[39]  G. Tseng,et al.  Biomarker profile in breast carcinomas presenting with bone metastasis. , 2009, International journal of clinical and experimental pathology.

[40]  Dino Amadori,et al.  The global breast cancer burden: variations in epidemiology and survival. , 2005, Clinical breast cancer.

[41]  L. Howell,et al.  Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions , 2007, Diagnostic cytopathology.

[42]  Haruo Tanaka,et al.  The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells. , 2009, Anticancer research.

[43]  Hellmut Samonigg,et al.  Novel Immunofluorescence Protocol for Multimarker Assessment of Putative Disseminating Breast Cancer Stem Cells , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[44]  L. Sherman,et al.  CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells. , 2002 .

[45]  A. Bankfalvi,et al.  Gains and losses of CD44 expression during breast carcinogenesis and tumour progression , 1998, Histopathology.

[46]  A. Astanehe,et al.  The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells , 2010, Oncogene.

[47]  M. Poupon,et al.  CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts , 2009, British Journal of Cancer.

[48]  R. Stern,et al.  CD44 Interaction with Na+-H+ Exchanger (NHE1) Creates Acidic Microenvironments Leading to Hyaluronidase-2 and Cathepsin B Activation and Breast Tumor Cell Invasion* , 2004, Journal of Biological Chemistry.

[49]  C. Yip,et al.  CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast. , 2006, The Malaysian journal of pathology.

[50]  B. Sullenger,et al.  RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  Chie-Pein Chen,et al.  Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type 1-matrix metalloproteinase. , 2009, International journal of cancer.

[52]  A. Afify,et al.  Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. , 2009, Experimental and molecular pathology.

[53]  A. Donnenberg,et al.  Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis , 2005, Journal of clinical pharmacology.

[54]  Eun-Kyung Lim,et al.  Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment , 2008, Biotechnology and bioengineering.

[55]  T. Yoneda,et al.  Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44. , 2003, Experimental cell research.

[56]  A. Schneeweiss,et al.  Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study , 2007, Anti-cancer drugs.

[57]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.